Why ICUI beats the market
Up 28% in a year while the S&P 500 rose 7%.
- It went from a loss in fiscal 2024 to a $732,000 profit in fiscal 2025, and diluted EPS went from -$4.83 to $0.03.
ICUI's Quality Score fell 3 points on Fri, Nov 20, to 8. Its price fell under its average of 8 days (2 chart checks stopped).
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 28% in a year while the S&P 500 rose 7%.
| The company | A $60M profit after losing money the year before |
| Latest filing | 8-K, Nov 5 |
Thu Dec 3: Piper Sandler 38th Annual…Investor conference · date confirmed.
After its last 4 reports it closed +5.3% on average, higher 4 of 4 times.
Averagefor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means
ICUI is #21 of 86 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 21 |
Sales over four quarters against a year before: ICUI -5.9%, HAE +4.1%.
Expected to report Thu Feb 18, after the close (in 89 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $560.4M, 4% more than a year ago; a profit of $1.07 a share, from a loss of $0.14.
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Infusion Consumables | $298M | $289M | $285M |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 5)
| Measure | Figure |
|---|---|
| GAAP diluted earnings per share | $2.89 to $3.29 |
“The Company is reaffirming its full year 2026 guidance but expects to end the fiscal year towards the higher end of the guidance range.”
From its results filing (SEC filing · Nov 5)
Sales grew 12% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 2.9% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 5, 2026 | -1.6% | +2.7% | +5.8% |
| Aug 6, 2026 | +9.6% | +10.9% | +10.1% |
| May 7, 2026 | 0.0% | +2.7% | -0.1% |
Sales grew in four of the last seven years, to $2.2B in 2025. It turned a profit in 2025 after a loss in 2024.
RSI 51.1, MACD below signal, above both averages. Not scored.
5 insiders sold $3.6M across 7 filings in the last 6 months. No open-market buys on record. The newest:
One trade disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: ICUI is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
“Our industry is highly competitive.”
ICUI scores 8 today, which Breakaway calls Average. It is #21 of 86 in Medical Devices by Quality Score, with 2 of 14 chart checks firing. Up 28% in a year while the S&P 500 rose 7%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ICUI scores 8 today, which Breakaway calls Average (6 to 10). That is #21 of 86 in Medical Devices by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ICUI's 8.
5 insiders sold $3.6M across 7 filings in the last 6 months. No open-market buys on record. The newest is David C. Greenberg, Director, who sold $156K on Nov 20. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.